Roth Capital Starts Bionano Genomics (BNGO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- S&P 500 and Nasdaq slip as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
UPDATE: Maxim Group Starts Bionano Genomics (BNGO) at Buy
September 25, 2018 7:41 AM EDT(Updated - September 25, 2018 7:57 AM EDT)
(updated to add analyst comments)
Maxim Group analyst Jason McCarthy initiates coverage on Bionano Genomics (NASDAQ: BNGO) with a Buy rating and a price target of $11.00.
McCarthy highlighted:
We are initiating coverage of Bionano Genomics with a Buy rating and $11 price target. Bionanos Saphyr could be the bridge between next-gen sequencing... More